脑机接口概念飙涨，多家公司回应！上交所也出手

Core Viewpoint - Multiple companies in the brain-computer interface (BCI) sector have indicated that their products are still in the early stages of market cultivation, with significant technological differences from international mainstream approaches [1][4][7] Group 1: Company Announcements - Companies have reported that their new products in the BCI field are still in the early market cultivation phase and have not yet achieved large-scale sales, thus not significantly impacting their financial performance [1][4][6] - 麦澜德 focuses on non-invasive BCI technology, which differs significantly from the invasive approaches currently prevalent internationally [1] - 伟思医疗 also emphasizes its focus on non-invasive technology and notes that its BCI products have not yet contributed significantly to overall revenue [4][6] - 翔宇医疗 has made investments in non-invasive BCI technology but acknowledges that its products have not yet achieved large-scale sales, resulting in a small revenue contribution [7] Group 2: Market Activity and Stock Performance - As of January 6, several BCI-related stocks have experienced a cumulative price increase of over 30% over three consecutive trading days, leading to abnormal trading activity [1][6] - The Shanghai Stock Exchange has issued an inquiry to 亚辉龙 regarding its strategic cooperation framework agreement with 深圳脑机星链科技有限公司, requesting additional disclosures about the technology and product status [10] - 亚辉龙's announcement revealed that its partner, 脑机星链, is developing non-invasive products that are still in early research stages and have not yet entered the registration phase [12]